[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"familial-pancreatic-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:familial-pancreatic-carcinoma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":36,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":5},"100645726","a-liquid-biopsy-for-pancreatic-cancer-early-detection-and-disease-monitoring-100645726",false,"NCT07700992","A Liquid Biopsy for Pancreatic Cancer Early-detection and Disease Monitoring","An Exosome-based and Machine-learning-powered Liquid Biopsy for Pancreatic Cancer Early-detection and Disease Monitoring","PANXEON","Inclusion Criteria:\n\n* Adult men or women aged ≥18 years at the time of plasma sample collection.\n* Classification as at increased risk for pancreatic ductal adenocarcinoma (PDAC) due to familial pancreatic cancer or hereditary pancreatic cancer syndrome\n* Classification as at increased risk for pancreatic ductal adenocarcinoma (PDAC) due to the presence of one (or more) mucinous pancreatic cystic lesion(s).\n* Availability of stored plasma samples collected as part of routine clinical care or surveillance and archived in the institutional biobank.\n* Availability of relevant clinical and demographic data in institutional medical records sufficient to address study objectives.\n* Prior provision of informed consent for biobanking and research use of biological samples and data\n\nExclusion Criteria:\n\n* Absence or insufficient quality\u002Fquantity of stored plasma samples for laboratory analysis.\n* Lack of clinical data required for cohort classification and\u002For outcome assessment.\n* History of pancreatic surgery or interventional procedures prior to plasma sample collection.\n* Concurrent active malignancy at the time of sample collection, other than non-melanoma skin cancer.\n* Samples collected outside routine clinical care or not compliant with institutional biobanking and data protection policies.","ALL","18 Years","99 Years",{"count":21,"type":22},600,"ESTIMATED","OBSERVATIONAL","Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy characterized by an asymptomatic early phase, late diagnosis, and poor survival, particularly in individuals who develop disease outside the context of early-stage detection. Early detection strategies are currently limited to imaging-based surveillance (MRI and endoscopic ultrasound) in selected high-risk populations, but these approaches are invasive, costly, and suboptimal in sensitivity. The aim of this study is to evaluate circulating cell-free and exosome-bound microRNAs as non-invasive biomarkers of PDAC risk and disease biology",[26,27,28,29,30,31,32,33,34,35],"Familial Pancreatic Cancer","Familial Pancreatic Carcinoma","Hereditary Pancreatic Cancer","Hereditary Pancreatitis","Pancreas Cancer","Pancreas Neoplasm","Pancreas Adenocarcinoma","Pancreas Cyst","Pancreatic Neoplasms","Intraductal Papillary Mucinous Neoplasm",[37,38],"Early detection","Liquid biopsy","RECRUITING","2026-07-13",{"date":42,"type":43},"2026-07-14","ACTUAL",{"date":45,"type":43},"2026-06-03",{"date":47,"type":22},"2032-01-30",{"name":49,"class":50},"Università Vita-Salute San Raffaele","OTHER"]